Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients
Abstract Background The use of circulating tumor cells (CTCs) as indicators of treatment response in metastatic colorectal cancer (mCRC) needs to be clarified. The objective of this study is to compare the Response Evaluation Criteria in Solid Tumors (RECIST) with the Cytologic Criteria Assessing Re...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-09-01
|
Series: | Journal of Translational Medicine |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12967-018-1624-2 |
id |
doaj-d576626d08b3421cb17d9eaa950cba15 |
---|---|
record_format |
Article |
spelling |
doaj-d576626d08b3421cb17d9eaa950cba152020-11-24T21:46:36ZengBMCJournal of Translational Medicine1479-58762018-09-0116111110.1186/s12967-018-1624-2Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patientsMayte Delgado-Ureña0Francisco G. Ortega1Diego de Miguel-Pérez2Alba Rodriguez-Martínez3Jose L. García-Puche4Hugh Ilyine5Jose A. Lorente6Jose Exposito-Hernandez7M. Carmen Garrido-Navas8Miguel Delgado-Ramirez9M. José Serrano10Integral Oncology Division, Clinical University HospitalLiquid Biopsy and Metastasis Research Group, GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government PTS, GranadaLiquid Biopsy and Metastasis Research Group, GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government PTS, GranadaIntegral Oncology Division, Clinical University HospitalIntegral Oncology Division, Clinical University HospitalDestiNA Genomics LtdLiquid Biopsy and Metastasis Research Group, GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government PTS, GranadaIntegral Oncology Division, Clinical University HospitalLiquid Biopsy and Metastasis Research Group, GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government PTS, GranadaDivision of Preventive Medicine and Public Health, CIBERESP, University of JaenIntegral Oncology Division, Clinical University HospitalAbstract Background The use of circulating tumor cells (CTCs) as indicators of treatment response in metastatic colorectal cancer (mCRC) needs to be clarified. The objective of this study is to compare the Response Evaluation Criteria in Solid Tumors (RECIST) with the Cytologic Criteria Assessing Response (CyCAR), based on the presence and phenotypic characterization of CTCs, as indicators of FOLFOX–bevacizumab treatment response. Methods 77 mCRC blood samples from FOLFOX–bevacizumab treated patients were analyzed to isolate CTCs before and after (12 and 24 weeks) treatment, using an immunomagnetic separation method. VEGFR expression was identified by double immunostaining. Results We observed a decrease of CTCs (42.8 vs. 18.2%) and VEGFR positivity (69.7% vs. 41.7%) after treatment. According to RECIST, 6.45% of the patients did not show any clinical benefit, whereas 93.55% patients showed a favorable response at 12 weeks. According to CyCAR, 29% had a non-favorable response and 71% patients did not. No significant differences were found between the response assessment by RECIST and CyCAR at 12 or 24 weeks. However, in the multivariate analysis, RECIST at 12 weeks and CyCAR at 24 weeks were independent prognostic factors for OS (HR: 0.1, 95% CI 0.02–0.58 and HR: 0.35, 95% CI 0.12–0.99 respectively). Conclusions CyCAR results were comparable to RECIST in evaluating the response in mCRC and can be used as an alternative when the limitation of RECIST requires additional response analysis techniques.http://link.springer.com/article/10.1186/s12967-018-1624-2Metastatic colorectal cancerBevacizumabCirculating tumor cellsRECISTCyCARPrognosis |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Mayte Delgado-Ureña Francisco G. Ortega Diego de Miguel-Pérez Alba Rodriguez-Martínez Jose L. García-Puche Hugh Ilyine Jose A. Lorente Jose Exposito-Hernandez M. Carmen Garrido-Navas Miguel Delgado-Ramirez M. José Serrano |
spellingShingle |
Mayte Delgado-Ureña Francisco G. Ortega Diego de Miguel-Pérez Alba Rodriguez-Martínez Jose L. García-Puche Hugh Ilyine Jose A. Lorente Jose Exposito-Hernandez M. Carmen Garrido-Navas Miguel Delgado-Ramirez M. José Serrano Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients Journal of Translational Medicine Metastatic colorectal cancer Bevacizumab Circulating tumor cells RECIST CyCAR Prognosis |
author_facet |
Mayte Delgado-Ureña Francisco G. Ortega Diego de Miguel-Pérez Alba Rodriguez-Martínez Jose L. García-Puche Hugh Ilyine Jose A. Lorente Jose Exposito-Hernandez M. Carmen Garrido-Navas Miguel Delgado-Ramirez M. José Serrano |
author_sort |
Mayte Delgado-Ureña |
title |
Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients |
title_short |
Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients |
title_full |
Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients |
title_fullStr |
Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients |
title_full_unstemmed |
Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients |
title_sort |
circulating tumor cells criteria (cycar) versus standard recist criteria for treatment response assessment in metastatic colorectal cancer patients |
publisher |
BMC |
series |
Journal of Translational Medicine |
issn |
1479-5876 |
publishDate |
2018-09-01 |
description |
Abstract Background The use of circulating tumor cells (CTCs) as indicators of treatment response in metastatic colorectal cancer (mCRC) needs to be clarified. The objective of this study is to compare the Response Evaluation Criteria in Solid Tumors (RECIST) with the Cytologic Criteria Assessing Response (CyCAR), based on the presence and phenotypic characterization of CTCs, as indicators of FOLFOX–bevacizumab treatment response. Methods 77 mCRC blood samples from FOLFOX–bevacizumab treated patients were analyzed to isolate CTCs before and after (12 and 24 weeks) treatment, using an immunomagnetic separation method. VEGFR expression was identified by double immunostaining. Results We observed a decrease of CTCs (42.8 vs. 18.2%) and VEGFR positivity (69.7% vs. 41.7%) after treatment. According to RECIST, 6.45% of the patients did not show any clinical benefit, whereas 93.55% patients showed a favorable response at 12 weeks. According to CyCAR, 29% had a non-favorable response and 71% patients did not. No significant differences were found between the response assessment by RECIST and CyCAR at 12 or 24 weeks. However, in the multivariate analysis, RECIST at 12 weeks and CyCAR at 24 weeks were independent prognostic factors for OS (HR: 0.1, 95% CI 0.02–0.58 and HR: 0.35, 95% CI 0.12–0.99 respectively). Conclusions CyCAR results were comparable to RECIST in evaluating the response in mCRC and can be used as an alternative when the limitation of RECIST requires additional response analysis techniques. |
topic |
Metastatic colorectal cancer Bevacizumab Circulating tumor cells RECIST CyCAR Prognosis |
url |
http://link.springer.com/article/10.1186/s12967-018-1624-2 |
work_keys_str_mv |
AT maytedelgadourena circulatingtumorcellscriteriacycarversusstandardrecistcriteriafortreatmentresponseassessmentinmetastaticcolorectalcancerpatients AT franciscogortega circulatingtumorcellscriteriacycarversusstandardrecistcriteriafortreatmentresponseassessmentinmetastaticcolorectalcancerpatients AT diegodemiguelperez circulatingtumorcellscriteriacycarversusstandardrecistcriteriafortreatmentresponseassessmentinmetastaticcolorectalcancerpatients AT albarodriguezmartinez circulatingtumorcellscriteriacycarversusstandardrecistcriteriafortreatmentresponseassessmentinmetastaticcolorectalcancerpatients AT joselgarciapuche circulatingtumorcellscriteriacycarversusstandardrecistcriteriafortreatmentresponseassessmentinmetastaticcolorectalcancerpatients AT hughilyine circulatingtumorcellscriteriacycarversusstandardrecistcriteriafortreatmentresponseassessmentinmetastaticcolorectalcancerpatients AT josealorente circulatingtumorcellscriteriacycarversusstandardrecistcriteriafortreatmentresponseassessmentinmetastaticcolorectalcancerpatients AT joseexpositohernandez circulatingtumorcellscriteriacycarversusstandardrecistcriteriafortreatmentresponseassessmentinmetastaticcolorectalcancerpatients AT mcarmengarridonavas circulatingtumorcellscriteriacycarversusstandardrecistcriteriafortreatmentresponseassessmentinmetastaticcolorectalcancerpatients AT migueldelgadoramirez circulatingtumorcellscriteriacycarversusstandardrecistcriteriafortreatmentresponseassessmentinmetastaticcolorectalcancerpatients AT mjoseserrano circulatingtumorcellscriteriacycarversusstandardrecistcriteriafortreatmentresponseassessmentinmetastaticcolorectalcancerpatients |
_version_ |
1725901239757045760 |